An overview of antibody-based cancer therapy / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1261-1268, 2012.
Artigo
em Chinês
| WPRIM
| ID: wpr-274667
ABSTRACT
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Approximate 17 monoclonal antibodies have been approved as cancer therapeutics since 1997. Antibody-drug conjugates (ADC) are powerful new treatment options for cancer, and naked antibodies have recently achieved remarkable success. The safety and effectiveness of therapeutic mAbs in oncology vary depending on the nature of the target antigen and the mechanisms of tumor cell killing. This review provides a summary of the current state of antibody-based cancer therapy, including the mechanisms of tumor cell killing by antibodies, tumor antigens as antibody targets, clinical effectiveness of antibodies in cancer patients and nanoparticles-based ADCs.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Terapêutica
/
Imunoconjugados
/
Usos Terapêuticos
/
Alergia e Imunologia
/
Nanopartículas
/
Anticorpos Monoclonais
/
Antígenos de Neoplasias
/
Neoplasias
/
Antineoplásicos
Limite:
Humanos
Idioma:
Chinês
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS